RCS - Avacta Group PLC - Hardman Res.: R&D accelerated to advance assets <Origin Href="QuoteRef">AVTG.L</Origin>
RNS Number : 6904TAvacta Group PLC16 October 2017Hardman Res.: R&D accelerated to advance assets
R&D accelerated to advance assets -Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry, despite its limitations. Avacta has made considerable progress towards its strategic goal to be ready to enter first-in-man Affimer trials by the end of 2019. Recent results highlighted significant progress made in its in-house therapeutic programmes with the first in-vivo studies showing safety, tolerability and efficacy of an Affimer. This adds to the de-risking of Affimer technology and attracting potential partners.
Please click here for the full report:
To contact us:
Contacts:
+44 20 7194 7622
Hardman & Co
Dr Martin Hall
35 New Broad Street
Dr Dorothea Hill
London
Dr Gregoire Pave
EC2M 1NH
Follow us on Twitter
@HardmanandCo
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors,and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNSThe company news service from the London Stock ExchangeENDNRAFFUSUMFWSEDS
Recent news on Avacta
See all newsREG - Avacta Group PLC - Update on AVA6000 Phase 1a Clinical Trial Progress
AnnouncementREG - AIM - AIM Notice - 19/03/2024
AnnouncementREG - Avacta Group PLC - Result of General Meeting
AnnouncementREG - Avacta Group PLC - Avacta Announces AVA6000 Poster at AACR
AnnouncementREG - Avacta Group PLC - Result of REX Retail Offer
Announcement